These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 29860366)

  • 1. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study.
    Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X
    J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease.
    Al-Bawardy B; Ramos GP; Willrich MAV; Jenkins SM; Park SH; Aniwan S; Schoenoff SA; Bruining DH; Papadakis KA; Raffals L; Tremaine WJ; Loftus EV
    Inflamm Bowel Dis; 2019 Feb; 25(3):580-586. PubMed ID: 30165638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
    Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases.
    Yarur AJ; Deepak P; Vande Casteele N; Battat R; Jain A; Okada L; Osterman M; Regueiro M
    Dig Dis Sci; 2021 Oct; 66(10):3563-3569. PubMed ID: 33089483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Introducing vedolizumab to clinical practice: who, when, and how?
    Bryant RV; Sandborn WJ; Travis SP
    J Crohns Colitis; 2015 Apr; 9(4):356-66. PubMed ID: 25687206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline levels of dynamic CD4
    Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
    BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting.
    Hemming-Harlo M; Merras-Salmio L; Nikkonen A; Kolho KL
    Eur J Pediatr; 2024 Jan; 183(1):313-322. PubMed ID: 37878072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
    Schulze H; Esters P; Hartmann F; Stein J; Christ C; Zorn M; Dignass A
    Scand J Gastroenterol; 2018 Jun; 53(6):670-676. PubMed ID: 29560811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease.
    Fernandes SR; Rodrigues IC; Serrazina J; Botto IA; Bernardo S; Gonçalves AR; Valente A; Moura Santos P; Correia LA; Marinho RT
    Scand J Gastroenterol; 2022 Oct; 57(10):1202-1208. PubMed ID: 35599574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
    Dubash S; Marianayagam T; Tinazzi I; Al-Araimi T; Pagnoux C; Weizman AV; Richette P; Tran Minh ML; Allez M; Singh A; Ciccia F; Hamlin J; Tan AL; Marzo-Ortega H; McGonagle D
    Rheumatology (Oxford); 2019 Jun; 58(6):963-968. PubMed ID: 30204909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab.
    Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M
    PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.
    Lamichhane N; Melas N; Bergqvist V; ; Ekholm NP; Olén O; Ludvigsson JF; Hjortswang H; Marsal J; Eriksson C; Halfvarson J
    Dig Dis Sci; 2024 Jun; 69(6):2175-2183. PubMed ID: 38637457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases.
    Singh S; Dulai PS; Vande Casteele N; Battat R; Fumery M; Boland BS; Sandborn WJ
    Aliment Pharmacol Ther; 2019 Oct; 50(8):848-857. PubMed ID: 31483522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumab.
    Ansari M; Glassner K; Irani M; Saleh A; Wang L; Ezeana C; Wong S; Perry C; Abraham B
    J Dig Dis; 2024 Feb; 25(2):91-99. PubMed ID: 38599667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.